Three Drugmakers with Strong Market Potential
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 20 2026
0mins
Should l Buy LLY?
Source: NASDAQ.COM
- Eli Lilly's Market Leadership: Eli Lilly is poised to dominate the chronic weight management market with its drug tirzepatide, projected to generate $62 billion in annual sales by 2030, establishing it as the world's best-selling medicine and showcasing its competitive strength in a rapidly growing sector.
- Vertex Pharmaceuticals' Unique Position: Vertex Pharmaceuticals holds a monopoly in cystic fibrosis drugs, targeting the genetic causes of the disease, with a projected 3% annual growth rate in the patient population from 2020 to 2025, ensuring consistent revenue and earnings for the company.
- Pfizer's Potential Rebound: Despite recent underperformance, Pfizer's stock trades at a low 9.3 times forward earnings compared to the healthcare sector's average of 17.4, and the company plans to initiate over 20 phase 3 trials, which could lead to new product launches and improved financial results.
- Innovation and Investment Synergy: Eli Lilly's focus extends beyond weight loss, as it develops or licenses new medicines across various fields, demonstrating strong innovative capabilities and financial performance, making it an attractive long-term investment option.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 878.240
Low
950.00
Averages
1192
High
1500
Current: 878.240
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ELI LILLY - TALTZ AND ZEPBOUND ACHIEVE PRIMARY AND ALL IMPORTANT SECONDARY ENDPOINTS SHOWING STATISTICAL SUPERIORITY OVER TALTZ MONOTHERAPY AT 36 WEEKS
- Primary and Secondary Endpoints: The study focuses on the primary and all key secondary endpoints for statistical superiority related to Total Tz Monotherapy at 36 weeks.
- Statistical Superiority: The aim is to demonstrate that Total Tz Monotherapy is statistically superior in its effects compared to other treatments.
See More
Phase 3B Data Revealed at AAD Annual Meeting Demonstrates Enhanced Efficacy of Lilly's Taltz (Ixekizumab) Combined with Zepbound (Tirzepatide) for Adults with Psoriatic Arthritis and Obesity
New Data Presentation: Phase 3 data for the drugs IxeKizumab (brand name: Taltz) and Tirzepatide (brand name: Zepbound) was presented at an annual meeting.
Efficacy Results: The data demonstrated superior efficacy for adults suffering from psoriatic arthritis and obesity.
See More
Eli Lilly Expands AI Drug Development Strategy with $2.75 Billion Insilico Agreement
- Strategic Partnership: Eli Lilly's agreement with Insilico Medicine, potentially worth up to $2.75 billion, grants Lilly exclusive rights to develop and sell any therapies resulting from the collaboration, underscoring its strong commitment to AI in drug development.
- Upfront Payments and Future Earnings: The pact includes upfront payments along with milestone payments and royalties based on future outcomes, reflecting Lilly's proactive stance in investing in new technologies to expedite drug development.
- Market Timing: With Lilly's obesity portfolio generating significant revenue, this partnership will further enhance its investments in AI, helping the company maintain a competitive edge in the fast-evolving pharmaceutical market.
- Accelerating Early Discoveries: This transaction illustrates how major pharmaceutical companies are rapidly and efficiently accelerating early-stage drug discoveries, with investors closely monitoring Lilly's AI initiatives to assess their long-term attractiveness and market potential.
See More
Pharma Stocks Pfizer and GSK Provide Safe Investment Options Amid Market Uncertainty: Charts
Pharmaceutical Stocks in Focus: Investors are increasingly interested in pharmaceutical stocks as a stable investment option amid market uncertainty.
Market Volatility Impact: The sector is gaining attention due to its steady demand and resilient earnings, which are less affected by economic fluctuations.
See More
Surging Oil Prices Impact Market Sentiment
- Oil Price Volatility: Crude oil prices surged 55% in March following Trump's threat to 'take the oil in Iran,' marking the largest monthly gain ever, which has heightened concerns about the potential impact on the U.S. economy and market sentiment.
- Government Shutdown Impact: Trump signed an executive order to ensure TSA employees are paid after Congress failed to reach a deal, which may lead to longer security wait times and higher airfare for travelers, further affecting consumer confidence.
- Tech Industry Legal Risks: Meta's two courtroom defeats reveal the legal liabilities tech companies face when researching product impacts, which could have significant implications for the AI industry, prompting firms to reassess the risks versus rewards of such research investments.
- Pharmaceutical Collaboration: Eli Lilly's $2.75 billion deal with Insilico Medicine aims to bring AI-developed drugs to the global market, which not only boosted Lilly's stock price but also highlights the rapidly growing potential of AI applications in the pharmaceutical sector.
See More
Eli Lilly's AI Investment: Implications for Its Stock Performance.
Eli Lilly's AI Integration: Eli Lilly is positioning itself as a leader in the healthcare industry's integration of artificial intelligence, indicating it has been proactive in this area.
Industry Response: The healthcare sector is currently working to adopt AI technologies, highlighting a broader trend towards innovation in medical practices.
See More
ELI LILLY - TALTZ AND ZEPBOUND ACHIEVE PRIMARY AND ALL IMPORTANT SECONDARY ENDPOINTS SHOWING STATISTICAL SUPERIORITY OVER TALTZ MONOTHERAPY AT 36 WEEKS
- Primary and Secondary Endpoints: The study focuses on the primary and all key secondary endpoints for statistical superiority related to Total Tz Monotherapy at 36 weeks.
- Statistical Superiority: The aim is to demonstrate that Total Tz Monotherapy is statistically superior in its effects compared to other treatments.
See More
Phase 3B Data Revealed at AAD Annual Meeting Demonstrates Enhanced Efficacy of Lilly's Taltz (Ixekizumab) Combined with Zepbound (Tirzepatide) for Adults with Psoriatic Arthritis and Obesity
New Data Presentation: Phase 3 data for the drugs IxeKizumab (brand name: Taltz) and Tirzepatide (brand name: Zepbound) was presented at an annual meeting.
Efficacy Results: The data demonstrated superior efficacy for adults suffering from psoriatic arthritis and obesity.
See More
Eli Lilly Expands AI Drug Development Strategy with $2.75 Billion Insilico Agreement
- Strategic Partnership: Eli Lilly's agreement with Insilico Medicine, potentially worth up to $2.75 billion, grants Lilly exclusive rights to develop and sell any therapies resulting from the collaboration, underscoring its strong commitment to AI in drug development.
- Upfront Payments and Future Earnings: The pact includes upfront payments along with milestone payments and royalties based on future outcomes, reflecting Lilly's proactive stance in investing in new technologies to expedite drug development.
- Market Timing: With Lilly's obesity portfolio generating significant revenue, this partnership will further enhance its investments in AI, helping the company maintain a competitive edge in the fast-evolving pharmaceutical market.
- Accelerating Early Discoveries: This transaction illustrates how major pharmaceutical companies are rapidly and efficiently accelerating early-stage drug discoveries, with investors closely monitoring Lilly's AI initiatives to assess their long-term attractiveness and market potential.
See More
Pharma Stocks Pfizer and GSK Provide Safe Investment Options Amid Market Uncertainty: Charts
Pharmaceutical Stocks in Focus: Investors are increasingly interested in pharmaceutical stocks as a stable investment option amid market uncertainty.
Market Volatility Impact: The sector is gaining attention due to its steady demand and resilient earnings, which are less affected by economic fluctuations.
See More
Surging Oil Prices Impact Market Sentiment
- Oil Price Volatility: Crude oil prices surged 55% in March following Trump's threat to 'take the oil in Iran,' marking the largest monthly gain ever, which has heightened concerns about the potential impact on the U.S. economy and market sentiment.
- Government Shutdown Impact: Trump signed an executive order to ensure TSA employees are paid after Congress failed to reach a deal, which may lead to longer security wait times and higher airfare for travelers, further affecting consumer confidence.
- Tech Industry Legal Risks: Meta's two courtroom defeats reveal the legal liabilities tech companies face when researching product impacts, which could have significant implications for the AI industry, prompting firms to reassess the risks versus rewards of such research investments.
- Pharmaceutical Collaboration: Eli Lilly's $2.75 billion deal with Insilico Medicine aims to bring AI-developed drugs to the global market, which not only boosted Lilly's stock price but also highlights the rapidly growing potential of AI applications in the pharmaceutical sector.
See More
Eli Lilly's AI Investment: Implications for Its Stock Performance.
Eli Lilly's AI Integration: Eli Lilly is positioning itself as a leader in the healthcare industry's integration of artificial intelligence, indicating it has been proactive in this area.
Industry Response: The healthcare sector is currently working to adopt AI technologies, highlighting a broader trend towards innovation in medical practices.
See More
